Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Philippines Gets Moving On Reg Reform: Asian Medtech Associations Regulatory Networking, October 2018

Executive Summary

The Asian Medtech Associations Regulatory Networking discussions this month focus on regulatory reforms in the Philippines, where good progress is being made on embedding a new set of medical device, IVD and labeling regulations. Also, updates from Thailand, Hong Kong and India. This series is hosted by Medtech Insight, along with the Asia Regulatory and Quality Consultancy (ARQon) and the Asia Regulatory Professionals Association (ARPA).

You may also be interested in...

Asian Regulatory Discussions: ASEANMed Nations Make Device Progress Despite Pandemic

Medtech industry representatives from Thailand, Myanmar, Indonesia, Singapore and the Philippines gave updates on regulatory actions being taken to control COVID-19 and other regulatory initiatives at local and ASEANMed level during a roundtable session.

Thailand Rolls Out IMDRF-Based Risk Classifications For Devices And Diagnostics

Thailand has opted to align with IMDRF principles on the classification of devices. The change also brings the Thai FDA into line with Asean Medical Device Directive principles.

Hong Kong Medtech Regulators Face Need For System Update

Speed and efficiency are apparently on the minds of Hong Kong's regulators, who have proposed to shorten approval times for medical device registrations, and are considering granting earlier approvals, subject to certain criteria. Stakeholders are showing guarded optimism in early responses.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts